Dementia Update 2003
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Clinical and scientific investigations in the field of dementia expanded greatly in the past two decades. Medline citations that addressed Alzheimer disease (AD), the most common dementing disorder, rose from 78 in 1980 to 987 in 1990 and to 1772 in 2000. Underscoring this increased body of knowledge, three practice parameters on dementia were published in 2001 by the Quality Standards Subcommittee of the American Academy of Neurology. Although some older studies are included for context, this review focuses on selected recent advances in dementia that are relevant for the practicing physician. Topics covered include: 1) diagnosis of dementia; 2) risk factors and biomarkers; 3) mild cognitive impairment; 4) the scientific basis for treatment advances in AD; and 5) other dementing disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“The first neuropathological examination of an individual immunized with A revealed evidence for both a Tlymphocyte meningoencephalitis and for clearance of A plaques from the neocortex.(142) Moreover, most immunized individuals (n = 24) enrolled at one participating site during the original study and followed for 1 ye…”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Moreover, some NSAIDs appear to decrease the production of A 1-42 in cultured cells, raising the possibility that at least some NSAIDs may directly affect amyloid pathology in the brain.(103) Although inflammatory mechanisms may contribute to neuronal injury and NSAIDs are being evaluated for the prevention of AD, the…”
Background(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“brain-plasma A equilibrium, thus acting as a peripheral A “sink” to cause reductions in brain A burden.(144,145) If the amyloid hypothesis indeed is relevant for AD, and if one or more of the anti-amyloid therapies prove to be safe and effective, it is conceivable that these disease-modifying approaches may provide me…”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 1×
“The Canadian Study of Health and Aging recently reported that increasing age, fewer years of education, and the 4 allele of apolipoprotein E are associated with an increased risk for AD, whereas use of nonsteroidal anti-inflammatory drugs (NSAIDs), consumption of wine and coffee, and regular physical activity are asso…”
Background
Cited by
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia
Bunch, T. J., Weiss, J. P., Crandall, B. G., May, H. T., Bair, T. L., Osborn, J. S., Anderson, J. L., Muhlestein, J. B., Horne, B. D., Lappe, D. L., et al. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2009.12.004 · Cited by 405
Areosa Sastre, A., Vernooij, R. W., González-Colaço Harmand, M., & Martínez, G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003804.pub2 · Cited by 272
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
“REVIEW ARTICLE published: 31 October 2014 doi: 10.3389/fnins.2014.00327”
BackgroundResultInfluential
Metadata
- Authors
- Morris, J. C.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2003-10
- Volume
- 17
- Issue
- 4
- Pages
- 245-258
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W2076804918
- Cited by
- 36
- References
- 38
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dementia Update 2003. https://app.cochat.ai/papers/10.1097/00002093-200310000-00010
- The paper
- Morris, J. C. (2003). Dementia Update 2003. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/00002093-200310000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.